Bernard W Futscher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1613356/publications.pdf

Version: 2024-02-01

64 papers

3,945 citations

35 h-index 59 g-index

65 all docs

65
docs citations

65 times ranked 5649 citing authors

#	Article	IF	CITATIONS
1	Role for DNA methylation in the control of cell type–specific maspin expression. Nature Genetics, 2002, 31, 175-179.	21.4	403
2	Role for DNA Methylation in the Regulation of miR-200c and miR-141 Expression in Normal and Cancer Cells. PLoS ONE, 2010, 5, e8697.	2.5	268
3	Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene, 1998, 17, 1807-1812.	5.9	221
4	Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis, 2000, 21, 1761-1765.	2.8	211
5	Epigenetic silencing of maspin gene expression in human breast cancers. , 2000, 85, 805-810.		157
6	Agglomerative Epigenetic Aberrations Are a Common Event in Human Breast Cancer. Cancer Research, 2008, 68, 8616-8625.	0.9	146
7	Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis, 2008, 29, 1500-1508.	2.8	113
8	Stepwise DNA Methylation Changes Are Linked to Escape from Defined Proliferation Barriers and Mammary Epithelial Cell Immortalization. Cancer Research, 2009, 69, 5251-5258.	0.9	113
9	miRNA Gene Promoters Are Frequent Targets of Aberrant DNA Methylation in Human Breast Cancer. PLoS ONE, 2013, 8, e54398.	2.5	110
10	Epigenetic Inactivation of the HOXA Gene Cluster in Breast Cancer. Cancer Research, 2006, 66, 10664-10670.	0.9	109
11	Arsenic Toxicology: Translating between Experimental Models and Human Pathology. Environmental Health Perspectives, 2011, 119, 1356-1363.	6.0	98
12	Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene, 2003, 22, 3624-3634.	5.9	88
13	Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Research, 2000, 28, 3233-3239.	14.5	83
14	Epigenetic mediated transcriptional activation of WNT5A participates in arsenical-associated malignant transformation. Toxicology and Applied Pharmacology, 2009, 235, 39-46.	2.8	78
15	Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis, 2002, 23, 2063-2080.	2.8	74
16	Methylation of CpG Island Transcription Factor Binding Sites Is Unnecessary for Aberrant Silencing of the Human MGMT Gene. Journal of Biological Chemistry, 1996, 271, 13916-13924.	3.4	72
17	Hypoxia perturbs aryl hydrocarbon receptor signaling and CYP1A1 expression induced by PCB 126 in human skin and liver-derived cell lines. Toxicology and Applied Pharmacology, 2014, 274, 408-416.	2.8	71
18	Genetic and Epigenetic Inactivation of Extracellular Superoxide Dismutase Promotes an Invasive Phenotype in Human Lung Cancer by Disrupting ECM Homeostasis. Molecular Cancer Research, 2012, 10, 40-51.	3.4	69

#	Article	IF	CITATIONS
19	Epigenetic regulation of normal human mammary cell type–specific miRNAs. Genome Research, 2011, 21, 2026-2037.	5.5	68
20	Selective variegated methylation of thep15 CpG island in acute myeloid leukemia., 1998, 78, 561-567.		63
21	Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochemical Pharmacology, 1994, 47, 1601-1606.	4.4	61
22	Arsenic exposure induces the Warburg effect in cultured human cells. Toxicology and Applied Pharmacology, 2013, 271, 72-77.	2.8	61
23	Aberrant Methylation of the Maspin Promoter Is an Early Event in Human Breast Cancer. Neoplasia, 2004, 6, 380-389.	5.3	61
24	Different Mutant/Wild-Type p53 Combinations Cause a Spectrum of Increased Invasive Potential in Nonmalignant Immortalized Human Mammary Epithelial Cells. Neoplasia, 2008, 10, 450-461.	5.3	60
25	Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations. Cell Cycle, 2014, 13, 3423-3435.	2.6	60
26	Transcription-terminating lesions induced by bifunctional alkylating agents in vitro. Carcinogenesis, 1989, 10, 1307-1314.	2.8	53
27	Identification of a Novel Structural Variant of the α6 Integrin. Journal of Biological Chemistry, 2001, 276, 26099-26106.	3.4	53
28	p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics, 2008, 9, 486.	2.8	49
29	Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecologic Oncology, 2006, 102, 319-324.	1.4	48
30	A suite of DNA methylation markers that can detect most common human cancers. Epigenetics, 2018, 13, 61-72.	2.7	48
31	Monomethylarsonous Acid Produces Irreversible Events Resulting in Malignant Transformation of a Human Bladder Cell Line Following 12 Weeks of Low-Level Exposure. Toxicological Sciences, 2010, 116, 44-57.	3.1	47
32	Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance., 1996, 66, 520-525.		46
33	Arsenicals produce stable progressive changes in DNA methylation patterns that are linked to malignant transformation of immortalized urothelial cells. Toxicology and Applied Pharmacology, 2009, 241, 221-229.	2.8	44
34	Human Pancreatic Carcinoma Cells Activate Maspin Expression Through Loss of Epigenetic Control. Neoplasia, 2003, 5, 427-436.	5.3	43
35	Optimal Search-Based Gene Subset Selection for Gene Array Cancer Classification. IEEE Transactions on Information Technology in Biomedicine, 2007, 11, 398-405.	3.2	40
36	Coordinate H3K9 and DNA methylation silencing of ZNFs in toxicant-induced malignant transformation. Epigenetics, 2013, 8, 1080-1088.	2.7	40

#	Article	IF	CITATIONS
37	Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2014, 59, 365-374.	2.3	39
38	MnSOD Up-Regulates Maspin Tumor Suppressor Gene Expression in Human Breast and Prostate Cancer Cells. Antioxidants and Redox Signaling, 2003, 5, 677-688.	5.4	38
39	Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types. F1000Research, 2018, 7, 211.	1.6	31
40	Agglomerates of aberrant DNA methylation are associated with toxicant-induced malignant transformation. Epigenetics, 2012, 7, 1238-1248.	2.7	30
41	Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2014, 775-776, 48-54.	1.7	29
42	A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics, 2015, 10, 1074-1083.	2.7	28
43	Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells. Frontiers in Cell and Developmental Biology, 2015, 3, 13.	3.7	25
44	5-Azacytidine Modulates the Response of Sensitive and Multidrug-Resistant K562 Leukemic Cells to Cytostatic Drugs. Blood Cells, Molecules, and Diseases, 2001, 27, 637-648.	1.4	24
45	DNA methylation biomarkers discovered <i>in silico</i> detect cancer in liquid biopsies from non-small cell lung cancer patients. Epigenetics, 2020, 15, 419-430.	2.7	23
46	Differentially Expressed MicroRNAs in Postpartum Breast Cancer in Hispanic Women. PLoS ONE, 2015, 10, e0124340.	2.5	23
47	Decreased CP-1 (NF-Y) Activity Results in Transcriptional Down-Regulation of Topoisomerase IIα in a Doxorubicin-Resistant Variant of Human Multiple Myeloma RPMI 8226. Biochemical and Biophysical Research Communications, 1997, 237, 217-224.	2.1	22
48	Epigenetic Regulation of the Cell Type-Specific Gene 14-3-3Ïf. Neoplasia, 2005, 7, 799-808.	5.3	22
49	Hypomethylation of the 14â€3â€3σ promoter leads to increased expression in nonâ€small cell lung cancer. Genes Chromosomes and Cancer, 2011, 50, 830-836.	2.8	22
50	Cell-Type Specific DNA Methylation Patterns Define Human Breast Cellular Identity. PLoS ONE, 2012, 7, e52299.	2.5	22
51	Epigenetic Changes During Cell Transformation. Advances in Experimental Medicine and Biology, 2013, 754, 179-194.	1.6	22
52	DNA?Damaging and Transcription-Terminating Lesions Induced by AF64A In Vitro. Journal of Neurochemistry, 1992, 58, 1504-1509.	3.9	21
53	Flipping the Epigenetic Switch. American Journal of Pathology, 2004, 164, 1883-1886.	3.8	18
54	Maintenance of mitochondrial genomic integrity in the absence of manganese superoxide dismutase in mouse liver hepatocytes. Redox Biology, 2013, 1, 172-177.	9.0	16

#	Article	IF	CITATIONS
55	The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia, 2004, 6, 187-94.	5.3	14
56	Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. Clinical Epigenetics, 2022, 14, 28.	4.1	9
57	Pharmacogenomics of the Polyamine Analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl] eicosane Tetrahydrochloride, CGC-11093, in the Colon Adenocarcinoma Cell Line HCT1161. Technology in Cancer Research and Treatment, 2006, 5, 553-564.	1.9	7
58	In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene. Journal of Cancer, 2013, 4, 104-116.	2.5	7
59	DNA methylation changes in biomarker loci occur early in cancer progression. F1000Research, 2019, 8, 2106.	1.6	7
60	Comparisons of PCR-based genome amplification systems using CpG island microarrays. Human Mutation, 2006, 27, 589-596.	2.5	5
61	DNA methylation changes in biomarker loci occur early in cancer progression. F1000Research, 0, 8, 2106.	1.6	5
62	Gene amplification affecting O6-alkylguanine-DNA alkyltransferase activity is not detected in nitrosourea resistant or sensitive human cell lines. Carcinogenesis, 1990, 11, 479-483.	2.8	4
63	Detecting differences in 5-methylcytosine using restriction enzyme isoschizomers: an endogenous control for complete digestion. Nucleic Acids Research, 1995, 23, 4740-4741.	14.5	3
64	The Epigenetic Basis of Cell Type Specificity. FASEB Journal, 2012, 26, 83.1.	0.5	O